Search research articles
Contact Us
Filters
Showing results (271-280 of 288) with videos related to
Page
of 29
Sort By:
Journal of Internal Medicine
|
February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
S Bringhen, A Milan, M D'Agostino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2004
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
G Fountzilas, H P Kalofonos, U Dafni, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
March 19, 2014
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma
E Kastritis, F Zagouri, A Symeonidis, et al.
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Leukemia
|
November 2, 2013
International Myeloma Working Group recommendations for global myeloma care
H Ludwig, J S Miguel, M A Dimopoulos, et al.
Seminars in Hematology
|
May 5, 2023
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients
S D'Sa, J V Matous, R Advani, et al.
Seminars in Hematology
|
April 26, 2023
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials
C S Tam, P Kapoor, J J Castillo, et al.
Leukemia
|
July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R Hájek, T Masszi, M T Petrucci, et al.
Leukemia
|
December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
H Ludwig, M Delforge, T Facon, et al.
Page
of 29
Search research articles
Search
Showing results (271-280 of 288) with videos related to
Sort By:
Page
of 29
Journal of Internal Medicine
|
February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension
S Bringhen, A Milan, M D'Agostino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2004
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
G Fountzilas, H P Kalofonos, U Dafni, et al.
Leukemia
|
December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia
|
March 19, 2014
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma
E Kastritis, F Zagouri, A Symeonidis, et al.
Leukemia
|
August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
P Moreau, D Joshua, W-J Chng, et al.
Leukemia
|
November 2, 2013
International Myeloma Working Group recommendations for global myeloma care
H Ludwig, J S Miguel, M A Dimopoulos, et al.
Seminars in Hematology
|
May 5, 2023
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients
S D'Sa, J V Matous, R Advani, et al.
Seminars in Hematology
|
April 26, 2023
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials
C S Tam, P Kapoor, J J Castillo, et al.
Leukemia
|
July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R Hájek, T Masszi, M T Petrucci, et al.
Leukemia
|
December 19, 2017
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
H Ludwig, M Delforge, T Facon, et al.
Page
of 29